nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—MTOR—ovarian cancer	0.696	1	CbGaD
Pimecrolimus—CYP3A4—Topotecan—ovarian cancer	0.0109	0.354	CbGbCtD
Pimecrolimus—CYP3A4—Vinorelbine—ovarian cancer	0.00768	0.25	CbGbCtD
Pimecrolimus—CYP3A4—Paclitaxel—ovarian cancer	0.0054	0.175	CbGbCtD
Pimecrolimus—CYP3A4—Docetaxel—ovarian cancer	0.0039	0.127	CbGbCtD
Pimecrolimus—MTOR—myometrium—ovarian cancer	0.00298	0.0649	CbGeAlD
Pimecrolimus—CYP3A4—Doxorubicin—ovarian cancer	0.00291	0.0945	CbGbCtD
Pimecrolimus—MTOR—embryo—ovarian cancer	0.00287	0.0624	CbGeAlD
Pimecrolimus—FKBP1A—myometrium—ovarian cancer	0.00268	0.0584	CbGeAlD
Pimecrolimus—MTOR—epithelium—ovarian cancer	0.00234	0.051	CbGeAlD
Pimecrolimus—FKBP1A—epithelium—ovarian cancer	0.0021	0.0458	CbGeAlD
Pimecrolimus—MTOR—endometrium—ovarian cancer	0.0021	0.0457	CbGeAlD
Pimecrolimus—FKBP1A—uterine cervix—ovarian cancer	0.00209	0.0454	CbGeAlD
Pimecrolimus—Everolimus—MTOR—ovarian cancer	0.00205	0.314	CrCbGaD
Pimecrolimus—FKBP1A—decidua—ovarian cancer	0.00199	0.0433	CbGeAlD
Pimecrolimus—MTOR—gonad—ovarian cancer	0.00195	0.0424	CbGeAlD
Pimecrolimus—MTOR—uterus—ovarian cancer	0.00193	0.0421	CbGeAlD
Pimecrolimus—FKBP1A—endometrium—ovarian cancer	0.00189	0.0411	CbGeAlD
Pimecrolimus—FKBP1A—gonad—ovarian cancer	0.00175	0.0381	CbGeAlD
Pimecrolimus—FKBP1A—uterus—ovarian cancer	0.00174	0.0379	CbGeAlD
Pimecrolimus—MTOR—female reproductive system—ovarian cancer	0.00174	0.0378	CbGeAlD
Pimecrolimus—MTOR—bone marrow—ovarian cancer	0.00164	0.0357	CbGeAlD
Pimecrolimus—MTOR—female gonad—ovarian cancer	0.00158	0.0344	CbGeAlD
Pimecrolimus—MTOR—vagina—ovarian cancer	0.00157	0.0342	CbGeAlD
Pimecrolimus—FKBP1A—female reproductive system—ovarian cancer	0.00156	0.034	CbGeAlD
Pimecrolimus—FKBP1A—bone marrow—ovarian cancer	0.00148	0.0321	CbGeAlD
Pimecrolimus—FKBP1A—female gonad—ovarian cancer	0.00142	0.031	CbGeAlD
Pimecrolimus—FKBP1A—vagina—ovarian cancer	0.00141	0.0308	CbGeAlD
Pimecrolimus—MTOR—testis—ovarian cancer	0.0014	0.0305	CbGeAlD
Pimecrolimus—Temsirolimus—MTOR—ovarian cancer	0.00138	0.212	CrCbGaD
Pimecrolimus—FKBP1A—testis—ovarian cancer	0.00126	0.0275	CbGeAlD
Pimecrolimus—Sirolimus—MTOR—ovarian cancer	0.00122	0.187	CrCbGaD
Pimecrolimus—Tacrolimus—MTOR—ovarian cancer	0.00122	0.187	CrCbGaD
Pimecrolimus—MTOR—lymph node—ovarian cancer	0.00102	0.0221	CbGeAlD
Pimecrolimus—FKBP1A—lymph node—ovarian cancer	0.000914	0.0199	CbGeAlD
Pimecrolimus—CYP3A4—female reproductive system—ovarian cancer	0.000511	0.0111	CbGeAlD
Pimecrolimus—Temsirolimus—ABCB1—ovarian cancer	0.000238	0.0365	CrCbGaD
Pimecrolimus—Infestation NOS—Paclitaxel—ovarian cancer	0.000235	0.00229	CcSEcCtD
Pimecrolimus—Infestation—Paclitaxel—ovarian cancer	0.000235	0.00229	CcSEcCtD
Pimecrolimus—Paraesthesia—Topotecan—ovarian cancer	0.000234	0.00228	CcSEcCtD
Pimecrolimus—Breast disorder—Docetaxel—ovarian cancer	0.000234	0.00228	CcSEcCtD
Pimecrolimus—Influenza like illness—Epirubicin—ovarian cancer	0.000233	0.00228	CcSEcCtD
Pimecrolimus—Urticaria—Chlorambucil—ovarian cancer	0.000233	0.00227	CcSEcCtD
Pimecrolimus—Arthralgia—Vinorelbine—ovarian cancer	0.000233	0.00227	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Melphalan—ovarian cancer	0.000232	0.00227	CcSEcCtD
Pimecrolimus—Dyspnoea—Topotecan—ovarian cancer	0.000232	0.00227	CcSEcCtD
Pimecrolimus—Abdominal pain—Chlorambucil—ovarian cancer	0.000231	0.00226	CcSEcCtD
Pimecrolimus—Body temperature increased—Chlorambucil—ovarian cancer	0.000231	0.00226	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Docetaxel—ovarian cancer	0.000231	0.00226	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	0.000231	0.00225	CcSEcCtD
Pimecrolimus—Skin exfoliation—Epirubicin—ovarian cancer	0.000229	0.00224	CcSEcCtD
Pimecrolimus—Paraesthesia—Melphalan—ovarian cancer	0.000229	0.00223	CcSEcCtD
Pimecrolimus—Conjunctivitis—Paclitaxel—ovarian cancer	0.000229	0.00223	CcSEcCtD
Pimecrolimus—Dyspnoea—Melphalan—ovarian cancer	0.000227	0.00222	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Topotecan—ovarian cancer	0.000225	0.00219	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Vinorelbine—ovarian cancer	0.000223	0.00217	CcSEcCtD
Pimecrolimus—Pain—Topotecan—ovarian cancer	0.000223	0.00217	CcSEcCtD
Pimecrolimus—Constipation—Topotecan—ovarian cancer	0.000223	0.00217	CcSEcCtD
Pimecrolimus—Epistaxis—Paclitaxel—ovarian cancer	0.000222	0.00216	CcSEcCtD
Pimecrolimus—Infection—Vinorelbine—ovarian cancer	0.000221	0.00216	CcSEcCtD
Pimecrolimus—Sinusitis—Paclitaxel—ovarian cancer	0.000221	0.00215	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Melphalan—ovarian cancer	0.00022	0.00215	CcSEcCtD
Pimecrolimus—Nervous system disorder—Vinorelbine—ovarian cancer	0.000219	0.00213	CcSEcCtD
Pimecrolimus—Pain—Melphalan—ovarian cancer	0.000218	0.00213	CcSEcCtD
Pimecrolimus—Skin disorder—Vinorelbine—ovarian cancer	0.000217	0.00211	CcSEcCtD
Pimecrolimus—Influenza like illness—Doxorubicin—ovarian cancer	0.000216	0.00211	CcSEcCtD
Pimecrolimus—Hypersensitivity—Chlorambucil—ovarian cancer	0.000216	0.0021	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Topotecan—ovarian cancer	0.000213	0.00208	CcSEcCtD
Pimecrolimus—Skin exfoliation—Doxorubicin—ovarian cancer	0.000212	0.00207	CcSEcCtD
Pimecrolimus—Rhinitis—Paclitaxel—ovarian cancer	0.000212	0.00206	CcSEcCtD
Pimecrolimus—Pharyngitis—Paclitaxel—ovarian cancer	0.000209	0.00204	CcSEcCtD
Pimecrolimus—Sirolimus—ABCB1—ovarian cancer	0.000209	0.0321	CrCbGaD
Pimecrolimus—Tacrolimus—ABCB1—ovarian cancer	0.000209	0.0321	CrCbGaD
Pimecrolimus—Pruritus—Chlorambucil—ovarian cancer	0.000207	0.00202	CcSEcCtD
Pimecrolimus—Urticaria—Topotecan—ovarian cancer	0.000207	0.00202	CcSEcCtD
Pimecrolimus—Body temperature increased—Topotecan—ovarian cancer	0.000206	0.00201	CcSEcCtD
Pimecrolimus—Abdominal pain—Topotecan—ovarian cancer	0.000206	0.00201	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	0.000203	0.00198	CcSEcCtD
Pimecrolimus—Urticaria—Melphalan—ovarian cancer	0.000203	0.00198	CcSEcCtD
Pimecrolimus—Pneumonia—Docetaxel—ovarian cancer	0.0002	0.00195	CcSEcCtD
Pimecrolimus—Diarrhoea—Chlorambucil—ovarian cancer	0.0002	0.00195	CcSEcCtD
Pimecrolimus—Paraesthesia—Vinorelbine—ovarian cancer	0.0002	0.00195	CcSEcCtD
Pimecrolimus—Infestation NOS—Docetaxel—ovarian cancer	0.000199	0.00194	CcSEcCtD
Pimecrolimus—Infestation—Docetaxel—ovarian cancer	0.000199	0.00194	CcSEcCtD
Pimecrolimus—Dyspnoea—Vinorelbine—ovarian cancer	0.000199	0.00194	CcSEcCtD
Pimecrolimus—Eye disorder—Paclitaxel—ovarian cancer	0.000197	0.00192	CcSEcCtD
Pimecrolimus—Flushing—Paclitaxel—ovarian cancer	0.000196	0.00191	CcSEcCtD
Pimecrolimus—Conjunctivitis—Docetaxel—ovarian cancer	0.000194	0.00189	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.000192	0.00188	CcSEcCtD
Pimecrolimus—Hypersensitivity—Topotecan—ovarian cancer	0.000192	0.00187	CcSEcCtD
Pimecrolimus—Pain—Vinorelbine—ovarian cancer	0.000191	0.00186	CcSEcCtD
Pimecrolimus—Constipation—Vinorelbine—ovarian cancer	0.000191	0.00186	CcSEcCtD
Pimecrolimus—Immune system disorder—Paclitaxel—ovarian cancer	0.000191	0.00186	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Paclitaxel—ovarian cancer	0.00019	0.00186	CcSEcCtD
Pimecrolimus—Hypersensitivity—Melphalan—ovarian cancer	0.000188	0.00183	CcSEcCtD
Pimecrolimus—Epistaxis—Docetaxel—ovarian cancer	0.000188	0.00183	CcSEcCtD
Pimecrolimus—Vomiting—Chlorambucil—ovarian cancer	0.000186	0.00182	CcSEcCtD
Pimecrolimus—Dermatitis exfoliative—Epirubicin—ovarian cancer	0.000185	0.0018	CcSEcCtD
Pimecrolimus—Pruritus—Topotecan—ovarian cancer	0.000184	0.0018	CcSEcCtD
Pimecrolimus—Erythema—Paclitaxel—ovarian cancer	0.000184	0.00179	CcSEcCtD
Pimecrolimus—Malnutrition—Paclitaxel—ovarian cancer	0.000184	0.00179	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000182	0.00178	CcSEcCtD
Pimecrolimus—Pruritus—Melphalan—ovarian cancer	0.000181	0.00176	CcSEcCtD
Pimecrolimus—Rhinitis—Docetaxel—ovarian cancer	0.000179	0.00175	CcSEcCtD
Pimecrolimus—Diarrhoea—Topotecan—ovarian cancer	0.000178	0.00174	CcSEcCtD
Pimecrolimus—Back pain—Paclitaxel—ovarian cancer	0.000178	0.00173	CcSEcCtD
Pimecrolimus—Pharyngitis—Docetaxel—ovarian cancer	0.000178	0.00173	CcSEcCtD
Pimecrolimus—Urticaria—Vinorelbine—ovarian cancer	0.000177	0.00173	CcSEcCtD
Pimecrolimus—Abdominal pain—Vinorelbine—ovarian cancer	0.000176	0.00172	CcSEcCtD
Pimecrolimus—Body temperature increased—Vinorelbine—ovarian cancer	0.000176	0.00172	CcSEcCtD
Pimecrolimus—Diarrhoea—Melphalan—ovarian cancer	0.000175	0.0017	CcSEcCtD
Pimecrolimus—Nausea—Chlorambucil—ovarian cancer	0.000174	0.0017	CcSEcCtD
Pimecrolimus—Dermatitis exfoliative—Doxorubicin—ovarian cancer	0.000171	0.00167	CcSEcCtD
Pimecrolimus—Face oedema—Epirubicin—ovarian cancer	0.000168	0.00164	CcSEcCtD
Pimecrolimus—Angioedema—Paclitaxel—ovarian cancer	0.000168	0.00164	CcSEcCtD
Pimecrolimus—Eye disorder—Docetaxel—ovarian cancer	0.000167	0.00163	CcSEcCtD
Pimecrolimus—Flushing—Docetaxel—ovarian cancer	0.000166	0.00162	CcSEcCtD
Pimecrolimus—Vomiting—Topotecan—ovarian cancer	0.000166	0.00162	CcSEcCtD
Pimecrolimus—Rash—Topotecan—ovarian cancer	0.000164	0.0016	CcSEcCtD
Pimecrolimus—Hypersensitivity—Vinorelbine—ovarian cancer	0.000164	0.0016	CcSEcCtD
Pimecrolimus—Dermatitis—Topotecan—ovarian cancer	0.000164	0.0016	CcSEcCtD
Pimecrolimus—Headache—Topotecan—ovarian cancer	0.000163	0.00159	CcSEcCtD
Pimecrolimus—Vomiting—Melphalan—ovarian cancer	0.000162	0.00158	CcSEcCtD
Pimecrolimus—Immune system disorder—Docetaxel—ovarian cancer	0.000162	0.00158	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Docetaxel—ovarian cancer	0.000161	0.00157	CcSEcCtD
Pimecrolimus—Rash—Melphalan—ovarian cancer	0.000161	0.00157	CcSEcCtD
Pimecrolimus—Dermatitis—Melphalan—ovarian cancer	0.000161	0.00157	CcSEcCtD
Pimecrolimus—Cough—Paclitaxel—ovarian cancer	0.00016	0.00156	CcSEcCtD
Pimecrolimus—Abdominal pain upper—Epirubicin—ovarian cancer	0.000159	0.00155	CcSEcCtD
Pimecrolimus—Pruritus—Vinorelbine—ovarian cancer	0.000158	0.00154	CcSEcCtD
Pimecrolimus—Breast disorder—Epirubicin—ovarian cancer	0.000158	0.00154	CcSEcCtD
Pimecrolimus—Arthralgia—Paclitaxel—ovarian cancer	0.000156	0.00153	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Epirubicin—ovarian cancer	0.000156	0.00152	CcSEcCtD
Pimecrolimus—Face oedema—Doxorubicin—ovarian cancer	0.000156	0.00152	CcSEcCtD
Pimecrolimus—Erythema—Docetaxel—ovarian cancer	0.000156	0.00152	CcSEcCtD
Pimecrolimus—Malnutrition—Docetaxel—ovarian cancer	0.000156	0.00152	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000155	0.00152	CcSEcCtD
Pimecrolimus—Nausea—Topotecan—ovarian cancer	0.000155	0.00151	CcSEcCtD
Pimecrolimus—Diarrhoea—Vinorelbine—ovarian cancer	0.000153	0.00149	CcSEcCtD
Pimecrolimus—Nausea—Melphalan—ovarian cancer	0.000152	0.00148	CcSEcCtD
Pimecrolimus—Asthma—Epirubicin—ovarian cancer	0.000151	0.00147	CcSEcCtD
Pimecrolimus—Influenza—Epirubicin—ovarian cancer	0.000151	0.00147	CcSEcCtD
Pimecrolimus—Back pain—Docetaxel—ovarian cancer	0.000151	0.00147	CcSEcCtD
Pimecrolimus—Oedema—Paclitaxel—ovarian cancer	0.00015	0.00146	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Paclitaxel—ovarian cancer	0.00015	0.00146	CcSEcCtD
Pimecrolimus—Infection—Paclitaxel—ovarian cancer	0.000149	0.00145	CcSEcCtD
Pimecrolimus—Abdominal pain upper—Doxorubicin—ovarian cancer	0.000147	0.00144	CcSEcCtD
Pimecrolimus—Nervous system disorder—Paclitaxel—ovarian cancer	0.000147	0.00143	CcSEcCtD
Pimecrolimus—Breast disorder—Doxorubicin—ovarian cancer	0.000146	0.00142	CcSEcCtD
Pimecrolimus—Skin disorder—Paclitaxel—ovarian cancer	0.000146	0.00142	CcSEcCtD
Pimecrolimus—Bronchitis—Epirubicin—ovarian cancer	0.000145	0.00141	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Doxorubicin—ovarian cancer	0.000144	0.00141	CcSEcCtD
Pimecrolimus—Vomiting—Vinorelbine—ovarian cancer	0.000142	0.00138	CcSEcCtD
Pimecrolimus—Rash—Vinorelbine—ovarian cancer	0.000141	0.00137	CcSEcCtD
Pimecrolimus—Dermatitis—Vinorelbine—ovarian cancer	0.00014	0.00137	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.00014	0.00137	CcSEcCtD
Pimecrolimus—Headache—Vinorelbine—ovarian cancer	0.00014	0.00136	CcSEcCtD
Pimecrolimus—Influenza—Doxorubicin—ovarian cancer	0.000139	0.00136	CcSEcCtD
Pimecrolimus—Asthma—Doxorubicin—ovarian cancer	0.000139	0.00136	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Epirubicin—ovarian cancer	0.000138	0.00134	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000137	0.00133	CcSEcCtD
Pimecrolimus—Cough—Docetaxel—ovarian cancer	0.000136	0.00133	CcSEcCtD
Pimecrolimus—Pneumonia—Epirubicin—ovarian cancer	0.000135	0.00132	CcSEcCtD
Pimecrolimus—Paraesthesia—Paclitaxel—ovarian cancer	0.000135	0.00131	CcSEcCtD
Pimecrolimus—Infestation—Epirubicin—ovarian cancer	0.000134	0.00131	CcSEcCtD
Pimecrolimus—Infestation NOS—Epirubicin—ovarian cancer	0.000134	0.00131	CcSEcCtD
Pimecrolimus—Bronchitis—Doxorubicin—ovarian cancer	0.000134	0.00131	CcSEcCtD
Pimecrolimus—Dyspnoea—Paclitaxel—ovarian cancer	0.000134	0.0013	CcSEcCtD
Pimecrolimus—Arthralgia—Docetaxel—ovarian cancer	0.000133	0.00129	CcSEcCtD
Pimecrolimus—Nausea—Vinorelbine—ovarian cancer	0.000132	0.00129	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000132	0.00128	CcSEcCtD
Pimecrolimus—Conjunctivitis—Epirubicin—ovarian cancer	0.000131	0.00127	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.00013	0.00126	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000129	0.00126	CcSEcCtD
Pimecrolimus—Constipation—Paclitaxel—ovarian cancer	0.000128	0.00125	CcSEcCtD
Pimecrolimus—Pain—Paclitaxel—ovarian cancer	0.000128	0.00125	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000127	0.00124	CcSEcCtD
Pimecrolimus—Oedema—Docetaxel—ovarian cancer	0.000127	0.00124	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Docetaxel—ovarian cancer	0.000127	0.00124	CcSEcCtD
Pimecrolimus—Epistaxis—Epirubicin—ovarian cancer	0.000127	0.00124	CcSEcCtD
Pimecrolimus—Infection—Docetaxel—ovarian cancer	0.000126	0.00123	CcSEcCtD
Pimecrolimus—Sinusitis—Epirubicin—ovarian cancer	0.000126	0.00123	CcSEcCtD
Pimecrolimus—Pneumonia—Doxorubicin—ovarian cancer	0.000125	0.00122	CcSEcCtD
Pimecrolimus—Nervous system disorder—Docetaxel—ovarian cancer	0.000125	0.00122	CcSEcCtD
Pimecrolimus—Infestation NOS—Doxorubicin—ovarian cancer	0.000124	0.00121	CcSEcCtD
Pimecrolimus—Infestation—Doxorubicin—ovarian cancer	0.000124	0.00121	CcSEcCtD
Pimecrolimus—Skin disorder—Docetaxel—ovarian cancer	0.000123	0.0012	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000123	0.0012	CcSEcCtD
Pimecrolimus—Rhinitis—Epirubicin—ovarian cancer	0.000121	0.00118	CcSEcCtD
Pimecrolimus—Conjunctivitis—Doxorubicin—ovarian cancer	0.000121	0.00118	CcSEcCtD
Pimecrolimus—Pharyngitis—Epirubicin—ovarian cancer	0.00012	0.00117	CcSEcCtD
Pimecrolimus—Urticaria—Paclitaxel—ovarian cancer	0.000119	0.00116	CcSEcCtD
Pimecrolimus—Abdominal pain—Paclitaxel—ovarian cancer	0.000119	0.00116	CcSEcCtD
Pimecrolimus—Body temperature increased—Paclitaxel—ovarian cancer	0.000119	0.00116	CcSEcCtD
Pimecrolimus—Epistaxis—Doxorubicin—ovarian cancer	0.000117	0.00114	CcSEcCtD
Pimecrolimus—Sinusitis—Doxorubicin—ovarian cancer	0.000117	0.00114	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000116	0.00113	CcSEcCtD
Pimecrolimus—Paraesthesia—Docetaxel—ovarian cancer	0.000114	0.00111	CcSEcCtD
Pimecrolimus—Dyspnoea—Docetaxel—ovarian cancer	0.000113	0.00111	CcSEcCtD
Pimecrolimus—Eye disorder—Epirubicin—ovarian cancer	0.000113	0.0011	CcSEcCtD
Pimecrolimus—Flushing—Epirubicin—ovarian cancer	0.000112	0.00109	CcSEcCtD
Pimecrolimus—Rhinitis—Doxorubicin—ovarian cancer	0.000112	0.00109	CcSEcCtD
Pimecrolimus—Pharyngitis—Doxorubicin—ovarian cancer	0.000111	0.00108	CcSEcCtD
Pimecrolimus—Hypersensitivity—Paclitaxel—ovarian cancer	0.00011	0.00108	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.00011	0.00107	CcSEcCtD
Pimecrolimus—Immune system disorder—Epirubicin—ovarian cancer	0.000109	0.00106	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Epirubicin—ovarian cancer	0.000109	0.00106	CcSEcCtD
Pimecrolimus—Pain—Docetaxel—ovarian cancer	0.000109	0.00106	CcSEcCtD
Pimecrolimus—Constipation—Docetaxel—ovarian cancer	0.000109	0.00106	CcSEcCtD
Pimecrolimus—Pruritus—Paclitaxel—ovarian cancer	0.000106	0.00103	CcSEcCtD
Pimecrolimus—Erythema—Epirubicin—ovarian cancer	0.000105	0.00102	CcSEcCtD
Pimecrolimus—Malnutrition—Epirubicin—ovarian cancer	0.000105	0.00102	CcSEcCtD
Pimecrolimus—Eye disorder—Doxorubicin—ovarian cancer	0.000104	0.00102	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000104	0.00101	CcSEcCtD
Pimecrolimus—Flushing—Doxorubicin—ovarian cancer	0.000104	0.00101	CcSEcCtD
Pimecrolimus—Diarrhoea—Paclitaxel—ovarian cancer	0.000103	0.001	CcSEcCtD
Pimecrolimus—Back pain—Epirubicin—ovarian cancer	0.000102	0.000991	CcSEcCtD
Pimecrolimus—Immune system disorder—Doxorubicin—ovarian cancer	0.000101	0.000984	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000101	0.000981	CcSEcCtD
Pimecrolimus—Body temperature increased—Docetaxel—ovarian cancer	0.0001	0.00098	CcSEcCtD
Pimecrolimus—Abdominal pain—Docetaxel—ovarian cancer	0.0001	0.00098	CcSEcCtD
Pimecrolimus—Malnutrition—Doxorubicin—ovarian cancer	9.72e-05	0.000948	CcSEcCtD
Pimecrolimus—Erythema—Doxorubicin—ovarian cancer	9.72e-05	0.000948	CcSEcCtD
Pimecrolimus—Vomiting—Paclitaxel—ovarian cancer	9.53e-05	0.00093	CcSEcCtD
Pimecrolimus—Rash—Paclitaxel—ovarian cancer	9.45e-05	0.000922	CcSEcCtD
Pimecrolimus—Dermatitis—Paclitaxel—ovarian cancer	9.45e-05	0.000921	CcSEcCtD
Pimecrolimus—Back pain—Doxorubicin—ovarian cancer	9.4e-05	0.000917	CcSEcCtD
Pimecrolimus—Headache—Paclitaxel—ovarian cancer	9.39e-05	0.000916	CcSEcCtD
Pimecrolimus—Hypersensitivity—Docetaxel—ovarian cancer	9.36e-05	0.000913	CcSEcCtD
Pimecrolimus—Cough—Epirubicin—ovarian cancer	9.17e-05	0.000894	CcSEcCtD
Pimecrolimus—Pruritus—Docetaxel—ovarian cancer	8.99e-05	0.000877	CcSEcCtD
Pimecrolimus—Arthralgia—Epirubicin—ovarian cancer	8.94e-05	0.000872	CcSEcCtD
Pimecrolimus—Nausea—Paclitaxel—ovarian cancer	8.91e-05	0.000869	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	8.88e-05	0.000866	CcSEcCtD
Pimecrolimus—Diarrhoea—Docetaxel—ovarian cancer	8.7e-05	0.000848	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Epirubicin—ovarian cancer	8.57e-05	0.000836	CcSEcCtD
Pimecrolimus—Oedema—Epirubicin—ovarian cancer	8.57e-05	0.000836	CcSEcCtD
Pimecrolimus—Infection—Epirubicin—ovarian cancer	8.52e-05	0.000831	CcSEcCtD
Pimecrolimus—Cough—Doxorubicin—ovarian cancer	8.48e-05	0.000827	CcSEcCtD
Pimecrolimus—Nervous system disorder—Epirubicin—ovarian cancer	8.41e-05	0.00082	CcSEcCtD
Pimecrolimus—Skin disorder—Epirubicin—ovarian cancer	8.33e-05	0.000812	CcSEcCtD
Pimecrolimus—Arthralgia—Doxorubicin—ovarian cancer	8.27e-05	0.000807	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	8.22e-05	0.000801	CcSEcCtD
Pimecrolimus—Vomiting—Docetaxel—ovarian cancer	8.08e-05	0.000788	CcSEcCtD
Pimecrolimus—Rash—Docetaxel—ovarian cancer	8.01e-05	0.000782	CcSEcCtD
Pimecrolimus—Dermatitis—Docetaxel—ovarian cancer	8.01e-05	0.000781	CcSEcCtD
Pimecrolimus—Headache—Docetaxel—ovarian cancer	7.96e-05	0.000777	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Doxorubicin—ovarian cancer	7.93e-05	0.000774	CcSEcCtD
Pimecrolimus—Oedema—Doxorubicin—ovarian cancer	7.93e-05	0.000774	CcSEcCtD
Pimecrolimus—Infection—Doxorubicin—ovarian cancer	7.88e-05	0.000769	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Epirubicin—ovarian cancer	7.81e-05	0.000762	CcSEcCtD
Pimecrolimus—Nervous system disorder—Doxorubicin—ovarian cancer	7.78e-05	0.000759	CcSEcCtD
Pimecrolimus—Skin disorder—Doxorubicin—ovarian cancer	7.7e-05	0.000751	CcSEcCtD
Pimecrolimus—Paraesthesia—Epirubicin—ovarian cancer	7.7e-05	0.000751	CcSEcCtD
Pimecrolimus—Dyspnoea—Epirubicin—ovarian cancer	7.64e-05	0.000745	CcSEcCtD
Pimecrolimus—Nausea—Docetaxel—ovarian cancer	7.55e-05	0.000736	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Epirubicin—ovarian cancer	7.4e-05	0.000722	CcSEcCtD
Pimecrolimus—Constipation—Epirubicin—ovarian cancer	7.33e-05	0.000715	CcSEcCtD
Pimecrolimus—Pain—Epirubicin—ovarian cancer	7.33e-05	0.000715	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	7.23e-05	0.000705	CcSEcCtD
Pimecrolimus—Paraesthesia—Doxorubicin—ovarian cancer	7.12e-05	0.000695	CcSEcCtD
Pimecrolimus—Dyspnoea—Doxorubicin—ovarian cancer	7.07e-05	0.00069	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Epirubicin—ovarian cancer	7.01e-05	0.000684	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Doxorubicin—ovarian cancer	6.85e-05	0.000668	CcSEcCtD
Pimecrolimus—Urticaria—Epirubicin—ovarian cancer	6.81e-05	0.000664	CcSEcCtD
Pimecrolimus—Pain—Doxorubicin—ovarian cancer	6.78e-05	0.000662	CcSEcCtD
Pimecrolimus—Constipation—Doxorubicin—ovarian cancer	6.78e-05	0.000662	CcSEcCtD
Pimecrolimus—Abdominal pain—Epirubicin—ovarian cancer	6.78e-05	0.000661	CcSEcCtD
Pimecrolimus—Body temperature increased—Epirubicin—ovarian cancer	6.78e-05	0.000661	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Doxorubicin—ovarian cancer	6.49e-05	0.000633	CcSEcCtD
Pimecrolimus—Hypersensitivity—Epirubicin—ovarian cancer	6.32e-05	0.000616	CcSEcCtD
Pimecrolimus—Urticaria—Doxorubicin—ovarian cancer	6.3e-05	0.000615	CcSEcCtD
Pimecrolimus—Abdominal pain—Doxorubicin—ovarian cancer	6.27e-05	0.000612	CcSEcCtD
Pimecrolimus—Body temperature increased—Doxorubicin—ovarian cancer	6.27e-05	0.000612	CcSEcCtD
Pimecrolimus—Pruritus—Epirubicin—ovarian cancer	6.06e-05	0.000592	CcSEcCtD
Pimecrolimus—Diarrhoea—Epirubicin—ovarian cancer	5.87e-05	0.000572	CcSEcCtD
Pimecrolimus—Hypersensitivity—Doxorubicin—ovarian cancer	5.84e-05	0.00057	CcSEcCtD
Pimecrolimus—Pruritus—Doxorubicin—ovarian cancer	5.61e-05	0.000547	CcSEcCtD
Pimecrolimus—Vomiting—Epirubicin—ovarian cancer	5.45e-05	0.000532	CcSEcCtD
Pimecrolimus—Diarrhoea—Doxorubicin—ovarian cancer	5.43e-05	0.000529	CcSEcCtD
Pimecrolimus—Rash—Epirubicin—ovarian cancer	5.4e-05	0.000527	CcSEcCtD
Pimecrolimus—Dermatitis—Epirubicin—ovarian cancer	5.4e-05	0.000527	CcSEcCtD
Pimecrolimus—Headache—Epirubicin—ovarian cancer	5.37e-05	0.000524	CcSEcCtD
Pimecrolimus—Nausea—Epirubicin—ovarian cancer	5.09e-05	0.000497	CcSEcCtD
Pimecrolimus—Vomiting—Doxorubicin—ovarian cancer	5.04e-05	0.000492	CcSEcCtD
Pimecrolimus—Rash—Doxorubicin—ovarian cancer	5e-05	0.000488	CcSEcCtD
Pimecrolimus—Dermatitis—Doxorubicin—ovarian cancer	5e-05	0.000487	CcSEcCtD
Pimecrolimus—Headache—Doxorubicin—ovarian cancer	4.97e-05	0.000485	CcSEcCtD
Pimecrolimus—Nausea—Doxorubicin—ovarian cancer	4.71e-05	0.00046	CcSEcCtD
Pimecrolimus—MTOR—Signaling by PDGF—PIK3CA—ovarian cancer	3.93e-05	0.000334	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—ovarian cancer	3.9e-05	0.000331	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—SMARCA4—ovarian cancer	3.9e-05	0.000331	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—PTEN—ovarian cancer	3.88e-05	0.000329	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	3.88e-05	0.000329	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—ovarian cancer	3.88e-05	0.000329	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—AKT1—ovarian cancer	3.87e-05	0.000329	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—IL6—ovarian cancer	3.84e-05	0.000326	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—IL6—ovarian cancer	3.82e-05	0.000324	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—IL6—ovarian cancer	3.8e-05	0.000323	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—EREG—ovarian cancer	3.8e-05	0.000323	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—TERT—ovarian cancer	3.8e-05	0.000322	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—IL6—ovarian cancer	3.78e-05	0.000321	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—AKT1—ovarian cancer	3.77e-05	0.00032	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—VEGFA—ovarian cancer	3.74e-05	0.000317	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—AKT1—ovarian cancer	3.73e-05	0.000316	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—PIK3CA—ovarian cancer	3.72e-05	0.000316	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—HRAS—ovarian cancer	3.72e-05	0.000316	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—HRAS—ovarian cancer	3.72e-05	0.000316	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—ovarian cancer	3.72e-05	0.000316	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—AKT1—ovarian cancer	3.71e-05	0.000315	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—STAT3—ovarian cancer	3.7e-05	0.000314	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—HRAS—ovarian cancer	3.69e-05	0.000313	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—HRAS—ovarian cancer	3.65e-05	0.00031	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—HRAS—ovarian cancer	3.64e-05	0.000309	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—TLR4—ovarian cancer	3.63e-05	0.000308	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—PIK3CA—ovarian cancer	3.56e-05	0.000302	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—AKT1—ovarian cancer	3.56e-05	0.000302	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—ovarian cancer	3.56e-05	0.000302	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—IL6—ovarian cancer	3.56e-05	0.000302	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—IL6—ovarian cancer	3.56e-05	0.000302	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—AKT1—ovarian cancer	3.54e-05	0.000301	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—MAPK3—ovarian cancer	3.54e-05	0.0003	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—IL6—ovarian cancer	3.53e-05	0.000299	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—ovarian cancer	3.53e-05	0.000299	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—AKT1—ovarian cancer	3.53e-05	0.000299	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CAV1—ovarian cancer	3.51e-05	0.000298	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—AKT1—ovarian cancer	3.51e-05	0.000298	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—IL6—ovarian cancer	3.5e-05	0.000297	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—AKT1—ovarian cancer	3.49e-05	0.000296	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—IL6—ovarian cancer	3.48e-05	0.000295	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—IL6ST—ovarian cancer	3.48e-05	0.000295	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—STAT3—ovarian cancer	3.47e-05	0.000295	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—NRAS—ovarian cancer	3.46e-05	0.000294	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—HRAS—ovarian cancer	3.44e-05	0.000292	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—ovarian cancer	3.44e-05	0.000292	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—MAPK1—ovarian cancer	3.37e-05	0.000286	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PPP2R1A—ovarian cancer	3.35e-05	0.000284	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—IL6ST—ovarian cancer	3.33e-05	0.000282	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—FASN—ovarian cancer	3.33e-05	0.000282	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—MAPK3—ovarian cancer	3.32e-05	0.000281	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PARP1—ovarian cancer	3.31e-05	0.000281	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—ovarian cancer	3.29e-05	0.00028	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—AKT1—ovarian cancer	3.28e-05	0.000279	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—ovarian cancer	3.28e-05	0.000279	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—AKT1—ovarian cancer	3.28e-05	0.000279	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—AKT1—ovarian cancer	3.26e-05	0.000276	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HDAC6—ovarian cancer	3.23e-05	0.000274	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—AKT1—ovarian cancer	3.23e-05	0.000274	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—AKT1—ovarian cancer	3.21e-05	0.000273	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—APC—ovarian cancer	3.2e-05	0.000271	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—SLC2A1—ovarian cancer	3.16e-05	0.000268	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—MAPK1—ovarian cancer	3.16e-05	0.000268	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—EGFR—ovarian cancer	3.16e-05	0.000268	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—ovarian cancer	3.15e-05	0.000268	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—AKT1—ovarian cancer	3.04e-05	0.000258	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—KRAS—ovarian cancer	2.98e-05	0.000253	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CDH1—ovarian cancer	2.96e-05	0.000251	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—PIK3CD—ovarian cancer	2.94e-05	0.000249	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PPP2R1A—ovarian cancer	2.91e-05	0.000247	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—ovarian cancer	2.91e-05	0.000247	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—YAP1—ovarian cancer	2.86e-05	0.000242	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—TP53—ovarian cancer	2.82e-05	0.00024	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PIK3CD—ovarian cancer	2.82e-05	0.00024	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PIK3CD—ovarian cancer	2.81e-05	0.000239	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—XIAP—ovarian cancer	2.8e-05	0.000238	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—PIK3CA—ovarian cancer	2.74e-05	0.000232	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SMARCA4—ovarian cancer	2.73e-05	0.000231	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PPP2R1A—ovarian cancer	2.69e-05	0.000228	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EREG—ovarian cancer	2.66e-05	0.000226	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TERT—ovarian cancer	2.66e-05	0.000226	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—ERBB2—ovarian cancer	2.6e-05	0.00022	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD8A—ovarian cancer	2.59e-05	0.00022	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—IL6—ovarian cancer	2.59e-05	0.000219	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—PIK3CB—ovarian cancer	2.56e-05	0.000217	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—HRAS—ovarian cancer	2.53e-05	0.000215	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PGR—ovarian cancer	2.5e-05	0.000212	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—ERBB2—ovarian cancer	2.49e-05	0.000212	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—ERBB2—ovarian cancer	2.48e-05	0.000211	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PIK3CB—ovarian cancer	2.46e-05	0.000209	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CAV1—ovarian cancer	2.46e-05	0.000209	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MTOR—ovarian cancer	2.45e-05	0.000208	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PIK3CB—ovarian cancer	2.45e-05	0.000208	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—IL6—ovarian cancer	2.43e-05	0.000206	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CDKN1B—ovarian cancer	2.4e-05	0.000204	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NME2—ovarian cancer	2.4e-05	0.000204	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ESR1—ovarian cancer	2.37e-05	0.000201	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL6ST—ovarian cancer	2.33e-05	0.000198	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PARP1—ovarian cancer	2.32e-05	0.000197	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CDKN1B—ovarian cancer	2.31e-05	0.000196	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CDKN1B—ovarian cancer	2.3e-05	0.000195	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CTNNB1—ovarian cancer	2.27e-05	0.000193	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—APC—ovarian cancer	2.24e-05	0.00019	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3CG—ovarian cancer	2.24e-05	0.00019	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—AKT1—ovarian cancer	2.24e-05	0.00019	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—PTEN—ovarian cancer	2.21e-05	0.000188	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CTNNB1—ovarian cancer	2.17e-05	0.000184	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TERT—ovarian cancer	2.13e-05	0.000181	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PTEN—ovarian cancer	2.13e-05	0.00018	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PTEN—ovarian cancer	2.12e-05	0.00018	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—TLR4—ovarian cancer	2.11e-05	0.000179	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL6ST—ovarian cancer	2.03e-05	0.000172	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—NRAS—ovarian cancer	1.98e-05	0.000168	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CAV1—ovarian cancer	1.97e-05	0.000168	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3CD—ovarian cancer	1.97e-05	0.000167	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—NRAS—ovarian cancer	1.9e-05	0.000161	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—STAT3—ovarian cancer	1.89e-05	0.000161	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—MAPK3—ovarian cancer	1.89e-05	0.000161	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—NRAS—ovarian cancer	1.89e-05	0.00016	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PPP2R1A—ovarian cancer	1.88e-05	0.00016	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IL6ST—ovarian cancer	1.87e-05	0.000159	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MAPK3—ovarian cancer	1.81e-05	0.000153	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—MAPK1—ovarian cancer	1.8e-05	0.000153	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—EGFR—ovarian cancer	1.8e-05	0.000153	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—APC—ovarian cancer	1.8e-05	0.000153	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CDH1—ovarian cancer	1.79e-05	0.000152	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MYC—ovarian cancer	1.76e-05	0.000149	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ERBB2—ovarian cancer	1.74e-05	0.000148	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—EGFR—ovarian cancer	1.73e-05	0.000147	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MAPK1—ovarian cancer	1.72e-05	0.000146	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—EGFR—ovarian cancer	1.72e-05	0.000146	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MTOR—ovarian cancer	1.72e-05	0.000146	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3CB—ovarian cancer	1.72e-05	0.000146	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PIK3CD—ovarian cancer	1.71e-05	0.000145	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—KRAS—ovarian cancer	1.7e-05	0.000144	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CXCL8—ovarian cancer	1.65e-05	0.00014	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—KRAS—ovarian cancer	1.63e-05	0.000139	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—KRAS—ovarian cancer	1.63e-05	0.000138	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CDKN1B—ovarian cancer	1.61e-05	0.000137	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PIK3CD—ovarian cancer	1.58e-05	0.000134	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CASP3—ovarian cancer	1.58e-05	0.000134	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL2—ovarian cancer	1.58e-05	0.000134	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—PIK3CA—ovarian cancer	1.56e-05	0.000133	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYTB—ovarian cancer	1.55e-05	0.000131	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCND1—ovarian cancer	1.54e-05	0.00013	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CTNNB1—ovarian cancer	1.52e-05	0.000129	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ERBB2—ovarian cancer	1.51e-05	0.000128	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PIK3CA—ovarian cancer	1.5e-05	0.000127	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TERT—ovarian cancer	1.49e-05	0.000127	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PIK3CA—ovarian cancer	1.49e-05	0.000127	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PIK3CB—ovarian cancer	1.49e-05	0.000127	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MMP9—ovarian cancer	1.49e-05	0.000127	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PTEN—ovarian cancer	1.48e-05	0.000126	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—HRAS—ovarian cancer	1.45e-05	0.000123	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CDKN1B—ovarian cancer	1.4e-05	0.000119	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—ERBB2—ovarian cancer	1.4e-05	0.000118	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—HRAS—ovarian cancer	1.39e-05	0.000118	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—IL6—ovarian cancer	1.38e-05	0.000117	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CAV1—ovarian cancer	1.38e-05	0.000117	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—HRAS—ovarian cancer	1.38e-05	0.000117	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PIK3CB—ovarian cancer	1.38e-05	0.000117	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL2—ovarian cancer	1.37e-05	0.000116	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PPP1CC—ovarian cancer	1.35e-05	0.000115	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—BRIP1—ovarian cancer	1.35e-05	0.000115	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—VEGFA—ovarian cancer	1.34e-05	0.000114	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ESR1—ovarian cancer	1.33e-05	0.000113	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—STAT3—ovarian cancer	1.33e-05	0.000113	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CTNNB1—ovarian cancer	1.32e-05	0.000112	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NRAS—ovarian cancer	1.32e-05	0.000112	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—IL6—ovarian cancer	1.32e-05	0.000112	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL6ST—ovarian cancer	1.31e-05	0.000111	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CDKN1B—ovarian cancer	1.29e-05	0.00011	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PTEN—ovarian cancer	1.29e-05	0.000109	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—AKT1—ovarian cancer	1.28e-05	0.000108	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MAPK3—ovarian cancer	1.27e-05	0.000107	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—APC—ovarian cancer	1.26e-05	0.000107	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CG—ovarian cancer	1.26e-05	0.000107	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MYC—ovarian cancer	1.23e-05	0.000105	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—AKT1—ovarian cancer	1.23e-05	0.000104	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CTNNB1—ovarian cancer	1.22e-05	0.000104	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—AKT1—ovarian cancer	1.22e-05	0.000104	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MAPK1—ovarian cancer	1.21e-05	0.000102	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—EGFR—ovarian cancer	1.21e-05	0.000102	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PTEN—ovarian cancer	1.19e-05	0.000101	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—STAT3—ovarian cancer	1.15e-05	9.79e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—NRAS—ovarian cancer	1.15e-05	9.76e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—KRAS—ovarian cancer	1.14e-05	9.66e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CD—ovarian cancer	1.11e-05	9.39e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—MAPK3—ovarian cancer	1.1e-05	9.35e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—STAT3—ovarian cancer	1.07e-05	9.04e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NRAS—ovarian cancer	1.06e-05	9.01e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—MAPK1—ovarian cancer	1.05e-05	8.9e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—EGFR—ovarian cancer	1.05e-05	8.89e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3CA—ovarian cancer	1.05e-05	8.87e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MAPK3—ovarian cancer	1.02e-05	8.63e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TP53—ovarian cancer	1.01e-05	8.59e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—KRAS—ovarian cancer	9.9e-06	8.4e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MYC—ovarian cancer	9.9e-06	8.4e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ERBB2—ovarian cancer	9.78e-06	8.3e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MAPK1—ovarian cancer	9.68e-06	8.21e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—EGFR—ovarian cancer	9.68e-06	8.21e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HRAS—ovarian cancer	9.68e-06	8.21e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CB—ovarian cancer	9.65e-06	8.19e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CXCL8—ovarian cancer	9.27e-06	7.87e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL6—ovarian cancer	9.26e-06	7.86e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—KRAS—ovarian cancer	9.14e-06	7.76e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PIK3CA—ovarian cancer	9.1e-06	7.72e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—YAP1—ovarian cancer	9.06e-06	7.69e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CDKN1B—ovarian cancer	9.06e-06	7.68e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CASP3—ovarian cancer	8.88e-06	7.53e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL2—ovarian cancer	8.86e-06	7.52e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCND1—ovarian cancer	8.64e-06	7.33e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CTNNB1—ovarian cancer	8.56e-06	7.26e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AKT1—ovarian cancer	8.55e-06	7.25e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HRAS—ovarian cancer	8.42e-06	7.14e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PIK3CA—ovarian cancer	8.4e-06	7.13e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MMP9—ovarian cancer	8.39e-06	7.12e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PTEN—ovarian cancer	8.34e-06	7.08e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL6—ovarian cancer	8.06e-06	6.84e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HRAS—ovarian cancer	7.77e-06	6.59e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—VEGFA—ovarian cancer	7.53e-06	6.39e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—STAT3—ovarian cancer	7.46e-06	6.33e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NRAS—ovarian cancer	7.44e-06	6.31e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IL6—ovarian cancer	7.44e-06	6.31e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—AKT1—ovarian cancer	7.43e-06	6.31e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—FASN—ovarian cancer	7.39e-06	6.27e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLC5A5—ovarian cancer	7.27e-06	6.17e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MAPK3—ovarian cancer	7.13e-06	6.05e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLC2A1—ovarian cancer	7.02e-06	5.96e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MYC—ovarian cancer	6.93e-06	5.88e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—AKT1—ovarian cancer	6.86e-06	5.82e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MAPK1—ovarian cancer	6.78e-06	5.75e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EGFR—ovarian cancer	6.78e-06	5.75e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP1B1—ovarian cancer	6.73e-06	5.71e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KRAS—ovarian cancer	6.4e-06	5.43e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	5.97e-06	5.06e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CA—ovarian cancer	5.88e-06	4.99e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TP53—ovarian cancer	5.69e-06	4.83e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ABCB1—ovarian cancer	5.54e-06	4.7e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—TYMS—ovarian cancer	5.44e-06	4.62e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HRAS—ovarian cancer	5.44e-06	4.62e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL6—ovarian cancer	5.21e-06	4.42e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AKT1—ovarian cancer	4.81e-06	4.08e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CAV1—ovarian cancer	4.39e-06	3.72e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CG—ovarian cancer	3.99e-06	3.39e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CD—ovarian cancer	3.51e-06	2.98e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CB—ovarian cancer	3.06e-06	2.6e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTEN—ovarian cancer	2.65e-06	2.24e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.87e-06	1.58e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AKT1—ovarian cancer	1.52e-06	1.29e-05	CbGpPWpGaD
